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Background. Non-invasive detection of coronary artery disease in dial-
ysis patients, a major cause of mortality, often remains difficult. The aim
of the study was to test the diagnostic and prognostic accuracies of
combined dipyridamole-exercise thallium imaging in dialysis patients.
Methods. Dipyridamole-exercise thallium imaging and coronary angiog-
raphy were both performed prospectively in 60 asymptomatic hemodialy-
sis patients who were followed up, long term, by recording any major
coronary event.
Results. Coronary angiography was abnormal in 13 patients (21%), and
there was abnormal thallium uptake in 17 patients. Sensitivity, specificity,
positive and negative predictive values, and overall accuracy of thallium to
detect a coronary artery disease were 92, 89, 71, 98 and 90%, respectively.
After a median follow-up of 2.8 years, 12 patients experienced at least one
major coronary event (4 cardiac deaths, 5 myocardial infarctions and 3
revascularizations). Eight of the 17 patients with abnormal thallium
uptake (47%) suffered a coronary event, compared to only 4 of the 43
patients (9%) with a normal thallium uptake (P , 0.001). The positive
prognostic predictive value of thallium imaging was 47% and its negative
predictive value was 91%. The probability of survival free of coronary
events was significantly higher in patients with normal thallium uptake
than in those with abnormal thallium uptake (crude risk ratio 7.6; P ,
0.001) even after adjustment for several risk factors for cardiovacular
disease (adjusted risk ratio 9.2; P , 0.005).
Conclusion. In dialysis patients, combined dipyridamole-exercise thal-
lium imaging is an acurate method for detecting coronary stenosis and for
predicting future coronary events.
Despite progress in dialysis technology, coronary artery
disease (CAD) remains a frequent condition and a major
cause of morbidity and mortality in chronic dialysis patients
[1, 2]. Currently, screening for CAD is not a standard
medical practice in dialysis patients, but is reserved for
patients with clinical or electrical coronary manifestations,
those awaiting allograft renal surgery, and diabetic patients.
Coronary angiography remains the most effective method
for detecting CAD [3] despite its high cost and the signif-
icant risk of complications in these patients [4], and is
considered as the standard method. Non-invasive methods
give variable results when tested in dialysis patients. The
use of chest pain or electrocardiographic abnormalities is
inadequate in dialysis patients. Chest pain, in particular, is
a very poor marker of CAD since a considerable proportion
of dialysis patients with CAD are asymptomatic, whereas
one third of those suffering angina have normal coronary
angiography findings [5]. Exercise testing, even combined
with myocardial perfusion imaging, is limited by the inabil-
ity of dialysis patients to perform sufficient exercise [6–8],
the frequent development of exercise hypertension and
difficulties in interpretation of exercise electrocardio-
graphic tracings in presence of left ventricular hypertrophy
(LVH). Dipyridamole thallium imaging is useful for pa-
tients unable to exercise, such as dialysis patients [9], but
there is a relative lack of specificity of thallium imaging [10,
11], limiting its reliability to detect CAD. Left ventricle
hypertrophy (LVH), which occurs in almost all dialysis
patients [12, 13], often leads to false positive results in
thallium imaging and even lower specificity [14–16]. Dipy-
ridamole is also a less sensitive stimulus for detection of
CAD than maximal exercise or a combination of dipyrid-
amole and submaximal exercise [17–19]. The true accuracy
of stress-thallium in dialysis patients has not been clearly
assessed, taking into account all these potential limitations.
Thallium imaging is also of value for predicting future
adverse cardiac events [20]. The prognostic power of
stress-thallium imaging has been clearly demonstrated in
some studies conducted in non-uremic [21, 22] and in
dialysis patients [23–25], but not in others [26, 27].
The aim of this prospective study was to test the diag-
nostic accuracy and prognostic value of stress-thallium 201
single photon emission computer tomography (SPECT) in
asymptomatic dialysis patients using a combination of a
high dose of dipyridamole and symptom-limited exercise.
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The diagnostic accuracy of thallium imaging was deter-
mined versus coronary angiography. We used two methods
to assess the prognostic value of thallium imaging: (1)
comparison of prevalence of coronary events occurring in
patients with normal and abnormal thallium uptake, and
determination of prognostic predictive values; (2) survival
analysis. The prognostic power of thallium was assessed
relative to the duration of the follow-up period (total
follow-up or first year) and to the extent of the myocardial
defect (small or large). The prognostic value of thallium
imaging was compared to that of coronary angiography and
to that of a simulated two-step strategy consisting of
thallium imaging in all patients, followed by coronary
angiography only in those with abnormal thallium uptake.
METHODS
Study population
Seventy-six of the 160 patients treated in the three
hemodialysis centers of the Nephrology Department were
prospectively selected, as a consecutive series based on the
following criteria: older than 35 years of age; hemodialysis
for more than six months; no overt CAD, angina or
electrical myocardial infarction; and stable hemodynamic
status without hypotension, severe hypertension or conges-
tive heart failure. Patients with left bundle branch block,
pacemakers, significant valvular or congenital heart dis-
ease, pulmonary disease or malignancy were excluded.
Written informed consent was obtained from each patient
and the study was approved by an ethics committee. Sixteen
patients, 13 women and 3 men, refused coronary angiogra-
phy. The remaining 60 patients were the study population.
There were 39 men and 21 women, aged from 36 to 76
years old (mean 6 SD 54 6 11), of whom 13 were black
African and 47 were Caucasian. The patients had been
given hemodialysis for between 1.5 to 17 years ago (mean 6
SD 6.4 6 3.3). The etiology of renal failure involved
glomerular disease in 34% of patients, interstitial disease in
15% of patients, vascular disease in 18% of patients,
diabetes in 14% of patients, and a polycystic disease in 11%
of patients. The cause of renal failure was unknown in 8%
of patients. Fifty-five patients (91%) were considered to be
hypertensive, as they had overt hypertension classically
diagnosed before beginning dialysis or because they were
taking antihypertensive medication. Hypertension was
treated during the follow-up period by beta blockers in 13
patients, calcium blockers in 23 patients, and angiotensin
converting enzyme inhibitors in 15 patients. Nine patients
had diabetes mellitus, 12 had cholesterol levels above 2.5
g/liter and 17 patients were smokers (more than 5 cigarettes
per day). Thirty patients (50%) had at least two risk factors
(hypertension being included as a risk factor). Mean he-
moglobin concentration was 10.9 6 1.3 g/dl (range 8.5 to
14), and 81% of patients were given erythropoietin. LVH,
defined as an indexed LV mass (LVM) of at least 134 g/m2
in men and 110 g/m2 in women, was found in 51 patients
(85%), and an ejection fraction (EF) lower than 50% in 7
patients (11%). LVM and EF were obtained by echocardi-
ography in the three months before coronary exploration
using classical methods: Devereux formula by M-mode
echocardiography for LVM [28] and a length-area calcula-
tion by two dimensional echocardiography for EF [29]. The
study population did not differ significantly from the unen-
rolled dialysis patients in terms of age, race, dialysis dura-
tion, etiology of renal failure, prevalence and treatment of
hypertension, prevalence of other risk factors, hemoglobin
rate, LVM and EF (Table 1). There were slightly, but
significantly more men in the study group than in the
general dialysis population (65% vs. 49%, P , 0.05).
Stress-thallium procedure
Beta blockers and calcium channel blocking treatments
were discontinued one week (for beta blockers) and two
days (for calcium channel blockers) before thallium imag-
ing. Theophylline and cafeine-containing beverages were
avoided and the patients abstained from food and drink for
two hours before the test. Each patient underwent a
thallium 201 SPECT using a combination of two stimuli:
dipyridamole and exercise. A high dose (0.7 mg/kg) of
dipyridamole was given intravenously for four minutes. A
symptom-limited upright bicycle exercise was started either
simultaneously or just after the dipyridamole infusion,
using a load of 30 W, subsequently increased by 30 W every
three minutes. One minute before peak exercise, 3 to 4.5
mCi of thallium, according to body wt, was injected into the
patient. “Stress” images were obtained five minutes of
thallium injection. An additional dose of 1 to 1.5 mCi of
thallium was given three hours 30 minutes later and rest or
“redistribution” images were obtained after 30 minutes.
Stress and rest scintigraphy were performed using a rotat-
ing Gamma camera (Elscint - 409, Haifa, Israel) equipped





Age years 54 6 11 52 6 12
Men % 65 45a
Caucasian % 78 75
Dialysis duration years 6.4 6 3.3 5.9 6 3.5
Glomerular disease % 34 35
Diabetes % 14 16
Vascular disease % 18 17
Interstitial disease % 15 13
Polycystic disease % 11 12
Hypertension % 91 85
High cholesterol % 20 22
Smokers % 28 26
Hemoglobin g/dl 10.9 6 1.3 11 6 1.5
LVH % 85 88
Low EF % 11 13
Abbreviations are: EF, ejection fraction; LVH, left ventricular hyper-
trophy.
a P , 0.05 study patients vs. unenrolled patients
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with a high resolution collimator. Thirty frames of 30
seconds each, separated by 6° clockwise were obtained,
starting at the 30° right anterior oblique side of the patient.
After exclusion of non-myocardial activity by projection
masking, slices were reoriented along three orthogonal axes
(short axis, vertical long axis and horizontal long axis). The
data were filtered by back projection using a hamming filter
and reconstructed. Electrocardiographic tracings and thal-
lium images were analyzed blindly by two independent
observers before coronary angiography was performed.
There was 95% interobserver agreement and a consensus
resolved the discrepancies. Electrical positivity was defined
as downsloping or horizontal ST-segment depression of at
least 1 mm. The electrocardiogram (E.C.G.) was uninter-
pretable when there was major LVH or repolarization
abnormalities at rest. The left ventricle was divided into 13
regions: the apex, and the apical, middle and basal seg-
ments of anterior, inferior, septal and lateral walls for
thallium imaging interpretation. Thallium uptake in each
segment was qualitatively interpreted as normal or abnor-
mal. Abnormalities were classed as reversible or fixed by
comparing stress and four-hour redistribution images. Ab-
normal thallium uptake was defined as perfusion-defect
reversible or fixed involving at least one myocardial seg-
ment, apart from the inferior basal segment. Only a revers-
ible defect was considered to be abnormal for this segment,
which was classically recognized as the site of increased
photon attenuation leading to frequent thallium artifacts
[30]. A scintigraphic extension score, defined as the number
of abnormal segments, was also obtained for each patient.
Coronary angiography
Coronary angiography was performed in each patient, in
the month following thallium imaging. The usual Seldinger
technique with multiple left and right anterior oblique
projections and cranio-caudal angulations was used. A
minimal number of coronary injections was performed and
left ventriculography avoided to prevent hyperhydratation.
Angiograms were blindly interpreted by two independent
observers, using a hand-held caliper (model EC-1; Sandhill
Scientific Incorporated, Littleton, CO, USA), and consen-
sus was obtained when necessary. The presence of signifi-
cant coronary disease was defined as a reduction in luminal
diameter of $ 70%.
Follow-up
All 60 patients were followed up for six months to four
years (mean 2.8 6 1 year) in the dialysis centers and major
coronary events were assessed by medical record review
and interviews of physicians, patients and their families.
The outcomes included sudden death (SD), coronary non-
sudden death (NSD), non-fatal myocardial infarction (MI)
and myocardial revascularization. Sudden death was de-
fined as death occurring within six hours of the onset of
symptoms or within 24 hours of the time that the victim was
last seen alive in a normal state of health. Coronary
non-sudden death was defined as death occurring with
acute MI or a myocardial revascularization procedure.
Myocardial infarction was classically defined as prolonged
chest pain accompanied by pathological Q waves or persis-
tent ST-segment modification, or high serum creatinine
phosphokinase levels. Myocardial revascularization by cor-
onary artery bypass graft surgery (CABG) or percutaneous
transluminal coronary angioplasty (PTCA) was proposed
during follow-up after the occurrence of non-controlled
angina or acute MI, or in presence of either three-vessel
disease or left main artery stenosis. Outcomes were classi-
fied in the following order of severity: death, myocardial
infarction and myocardial revascularization. Only the most
severe outcome was considered in patients who developed
several complications.
Statistical analysis
Values are presented as mean 6 SD. Intergroup compar-
isons were performed by either the unpaired t-test or the
chi-square test. A value of P , 0.05 was considered as
significant. The sensitivity, specificity, positive and negative
predictive values and overall accuracy (percent correctly
classified) of thallium imaging were calculated to assess the
diagnostic capacity of thallium to detect a CAD defined as
an abnormal coronary angiography. Two methods were
used to assess the prognostic value of thallium, imaging: (1)
comparison of the prevalence of coronary events in the two
groups with normal or abnormal thallium uptake by chi-
square test, and calculation of positive and negative pre-
dictive values of thallium imaging for predicting future
coronary events; (2) comparison of the probability of
surviving with no coronary event for patients with normal
and abnormal thallium uptakes estimating a crude risk
ratio by univariate analysis, and an adjusted risk ratio by
Cox’s multivariate model [31], including age, sex, race,
dialysis duration, and presence of hypertension, diabetes,
high cholesterol levels, smoking, LVH and low EF. Survival
curves were produced using the Kaplan-Meier method. The
same methods were used to assess the prognostic value of
coronary angiography, and of a two-step strategy involving
scintigraphy in all patients followed by coronary angiogra-
phy only in those with abnormal thallium uptake. The
overall prognostic accuracy of thallium imaging, coronary
angiography and the two-step strategy was compared in
pairs using a test proposed by Bloch [32].
RESULTS
Coronary angiography
Thirteen patients (21%) had abnormal coronary angiog-
raphy results with significant large-vessel coronary disease.
Seven patients presented with one-vessel stenosis involving
the left anterior descending artery (LAD) in 2 cases and the
right coronary artery (RA) in 5 cases. Five patients had
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two-vessel disease involving the RA and either the LAD (2
cases) or the circumflex artery (3 cases). One patient had
three-vessel disease. There were no coronary events or
serious general complications during catheterization of the
patients and emergency dialysis was not required in any
case, but a dialysis session was systematically performed 24
hours after coronary angiography.
Diagnostic accuracy of thallium imaging
Patients achieved 82 6 16% of their predicted maximum
heart rate during dipyridamole-exercise thallium testing.
One patient experienced typical chest pain. There was
ischemic electrocardiographic abnormality in 3 patients
and the E.C.G. was uninterpretable in 9 others. Seventeen
patients had an abnormal thallium uptake (Group 1) with a
reversible myocardial defect in the posterior lateral region
in 13 patients, and the anterior, septal, apical zone in 4
patients. The remaining 43 patients all had normal thallium
uptake and were assigned to Group 2. The extent of the
perfusion defect was between 1 and 7 segments (mean
3.5 6 1) with a large defect ($4 segments) in 9 patients.
Thallium imaging and coronary angiography results were
both normal in 42 patients and both abnormal in 12
patients. In 5 patients, a reversible myocardial defect, in the
posterior wall in each case, was detected despite normal
coronary angiography result. Another patient with right
coronary artery stenosis had normal thallium uptake. Thus,
in a dialysis population characterized by a CAD prevalence
of 21%, the sensitivity of thallium imaging was 92%. It was
89% specific with a positive predictive value of 71%, a
negative predictive value of 98% and was 90% acurate
overall (confidence interval, CI 95% was 82 to 98%).
Long-term follow up
Prognostic predictive value of thallium imaging and coro-
nary angiography. During a median follow-up period of 2.8
years, 12 patients experienced at least one major coronary
event: 3 SD, 1 NSD following a CABG, 5 MI, 2 PTCA and
1 CABG. Eight patients in group 1 (47%) had one major
coronary event (2 SD, 1 NSD, 2 MI, 2 PTCA and 1 CABG)
compared to 4 (9%) in group 2 (1 SD and 3 MI; P , 0.001).
Of the 3 SD cases, a coronary origin with a typical history
could be established in only one patient from group 1.
When the 2 SD of unknown origin were excluded (1 in each
group), the difference in the prevalence of coronary events
was significantly different in the two groups (44% in group
1 vs. 7% in group 2, P , 0.001). The prognostic positive
predictive value of thallium imaging was 47% and its
negative predictive value was 91%. Eight of the 13 patients
(61%) with abnormal coronary angiography results had one
major coronary event (all also had abnormal thallium
uptake), whereas only 4 of the 47 patients (9%) with
normal coronary angiography (P , 0.001) had a major
coronary event. Thus, the positive and negative predictive
values of coronary angiography were 61 and 91%, respec-
tively. In the two-step strategy, 12 patients had both
abnormal thallium uptake and abnormal coronary angiog-
raphy results and 8 of these had a coronary event (67%)
compared to only 4 of the 48 patients (8%)with normal
thallium uptake or abnormal thallium uptake associated
with normal coronary angiography results (P , 0.001).
Thus, using the two-step strategy, the positive and negative
predictive values of both abnormal thallium uptake and
coronary angiography were 67% and 92%, respectively.
The overall prognostic accuracies of thallium imaging and
coronary angiography were not significantly different (78
vs. 85%, NS). The overall prognostic accuracy of thallium
imaging was signficantly lower than that of the two-step
strategy (78 vs. 87%, P , 0.01). The overall accuracies of
coronary angiography and the two-step strategy were not
significantly different (Fig. 1). The predictive value of a
large defect in thallium uptake (4 segments or more) was
analyzed. Of the 9 patients with a large defect in thallium
uptake, 6 (67%) had a coronary event, compared to only 6
of the remaning 51 patients (12%; P , 0.001). Hence, the
positive and negative predictive values of a large defect in
thallium uptake were 67% and 88%, respectively. The
capacity of thallium imaging to predict a coronary event in
the first year was also assessed. Seven coronary events
occurred during the first year, 6 in Group 1 (41%) and 1 in
Group 2 (2%; P , 0.001). Thus, the positive predictive
value of thallium for coronary events in the first year was
35% and the negative predictive value was 98%.
Survival analysis. The probability of surviving with no
coronary event was significantly higher in patients with
normal thallium uptake than in those with abnormal thal-
lium uptake. This was shown both by univariate analysis
(crude risk ratio 5 7.6, P , 0.001; Fig. 2) and multivariate
analysis (adjusted risk ratio 5 9.2, P , 0.005). Similar
Fig. 1. Comparison of the overall prognostic accuracy of the three
methods: thallium, coronary angiography, and the two-step strategy.
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results were obtained with coronary angiography, which
had a crude risk ratio of 11.3 (P , 0.001) and an adjusted
risk ratio of 14.2 (P , 0.001) In the two-step strategy,
abnormal thallium uptake and coronary angiography re-
sults predicted future coronary events more accurately than
either abnormal thallium uptake or coronary angiography
alone, with a crude risk ratio of 14.5 (P , 0.001) and an
adjusted risk ratio of 63.2 (P , 0.001).
DISCUSSION
In an asymptomatic hemodialysis population, character-
ized by the 21% occurrence of CAD, dipyridamole-exercise
thallium 201-SPECT accurately detected CAD and identi-
fied a group at low risk of coronary events.
Diagnostic accuracy of stress-thallium in hemodialysis
patients
To date, there is no accurate CAD diagnostic strategy for
dialysis patients, and the role of non-invasive methods, in
particular, was not clearly established [33, 34]. Coronary
angiography is the standard method for diagnosis of CAD
[4], but its use is limited by its high cost and a risk of
complications [5]. Exercise testing, even coupled with iso-
topic imaging, is limited by the inability of dialysis patients
to perform high level of exercise [6–8]. The low exercise
capacity of these patients results principally from anemia
[35] and reduction of muscular mass, whereas cardiac
adaptation is generally preserved until the advanced stages
of uremic cardiomyopathy. Our patients were able to
perform high levels of exercise. Another group has recently
reported similar findings [25]. The correction of anemia by
erythropoietin, which is currently used for this purpose,
may improve exercise performance in dialysis patients [35].
Both the frequent development of exercise hypertension in
hypertensive patients and difficulty in interpreting electri-
cal exercise tracings in cases of LVH also limit exercise
testing. Dipyridamole-thallium was proposed to circumvent
the problems of the inability to exercise. The method was
initially reported to be very acurrate [9], but these data
related to diabetic dialysis patients with a high prevalence
of CAD (about 50%) and could not be extrapolated to the
general dialysis population, which has a lower prevalence of
CAD of about 20% [2, 36]. Dipyridamole-thallium imaging
is chiefly limited by a lack of specificity [10, 11] for reasons
that are not clearly understood. Nevertheless, isotopic
attenuation in the posterior wall [30] and LVH [14–16] may
both generate false-positive results in thallium imaging.
The effect of LVH on thallium imaging is unclear, and
recent studies have found either normal thallium distribu-
tion [37] or false negative results [38] in hypertensive
patients with LVH. Dipyridamole is a less sensitive stimu-
lus for detection of CAD than maximal exercise, but its use
with submaximal exercise is as accurate as maximal exercise
alone. This may be a useful alternative method for patients
unable to perform maximal exercise [17–19]. In this study,
undertaken in a representative hemodialysis population
with a prevalence of CAD of 20%, dipyridamole-exercise
thallium 201 SPECT accurately detected CAD with a
sensitivity and specificity of about 90%. With a negative
predictive value of 98%, thallium imaging can be used to
rule out CAD and thus to avoid unnecessary coronary
angiography. The low positive predictive value (71%) may
be due to the high frequency of false-positive results with
thallium imaging (5 of 17 patients). The false-positives were
all associated with the posterior wall and were related to
either isotopic attenuation or major LVH. The high accu-
racy of thallium imaging we obtained may be due to the
strict methodology used in our protocol, with a combina-
tion of a high dose of dipyridamole and submaximal but
relatively high levels of exercise (82% of the maximum
predicted heart rate), and withdrawal of any coronary
medication before the test.
Prognostic value of stress thallium in hemodialysis
patients
The prognostic value of stress-thallium imaging has been
established in numerous conditions [20], particularly in
patients with known CAD, after myocardial infarction or
during peripheral vascular surgery [21, 22]. In dialysis
patients, dipyridamole or exercise-thallium imaging also
help to identify patients at low risk of cardiac events during
long-term follow-up or after renal allograft surgery [23–25].
However, several studies have contested this finding and
have suggested that the routine use of dipyridamole thal-
lium imaging for preoperative screening of patients under-
going vascular surgery is not justified [26, 27]. In this
present study, stress-thallium imaging with a negative pre-
dictive value of 98% almost perfectly identified a subgroup
of hemodialysis patients who did not suffer coronary events
in the first year. This predictive prognostic value derives
from the ability of thallium imaging to detect the presence
Fig. 2. Survival curves (free of coronary event) in patients with abnormal
(M; group 1) and normal (E); group 2) thallium uptakes.
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and extent of jeopardized viable myocardium manifested as
a reversible perfusion defect [39]. Moreover, previous
studies have established that the presence of transient
defect in thallium uptake is a better predictor of future
cardiac events than the presence of anatomic coronary
disease [39, 40]. In dialysis patients, we did not find any
advantage of thallium imaging over coronary angiography
as a prognostic marker, but this requires further assessment
on a large dialysis population. In our small group of
patients, coronary angiography was more accurate than
thallium imaging in terms of positive predictive value, both
having similar negative predictive values. This probably
results from the existence of frequent isotopic artifacts in
the posterior wall in our series of patients. We have also
evaluated the prognostic value of a currently strategy used
involving thallium imaging in all dialysis patients followed
by coronary angiography in those with a myocardial defect.
This two-step strategy provided the best method leading to
an “anatomical” diagnosis of CAD in all cases, and a strong
prognostic capacity as shown by the high predictive values
and a high adjusted risk ratio in a multivariate model (risk
ratio 5 63.2, P , 0.001). The prognostic value of the extent
of the defect in thallium uptake, previously established in a
general non-uremic population [21, 22], was similar to that
found for the hemodialysis patients in our study. Thus, in
our study, presence of a large perfusion defect (4 segments
or more) improved the positive predictive value of thallium
imaging (the capacity to identify hemodialysis patients at
high coronary risk), while maintaining a high negative
predictive value.
Study limitations
The findings of the present study were obtained in a
selected group of asymptomatic dialysis patients. Neverthe-
less, the study patients constituted a large representative
sample of the total hemodialysis population in the Nephrol-
ogy Department. Thus, the 60 study patients did not differ
from other patients of the 160 dialysis patients in our
department in terms of the main demographic and clinical
criteria. Only the proportion of men was slightly, but
significantly, higher in the study population (65 vs. 49%,
P , 0.05). This could lead to some overestimation of the
prevalence of CAD and of the positive predictive value of
thallium imaging for dectection of CAD or prediction of
future coronary events in dialysis patients. To test diagnos-
tic and prognostic accuracies of stress-thallium imaging, we
selected asymptomatic dialysis patients for the following
reasons: (1) Most dialysis patients are free of clinical
coronary manifestations. (2) Chest pain and electrocardio-
graphic abnormalities are often difficult to interpret. Chest
pain in particular is a poor marker of CAD since a large
proportion of dialysis patients with CAD are asymptomatic
whereas one third of those suffering angina have normal
coronary angiography findings [5]. (3) Some asymptomatic
patients may benefit from myocardial revascularization and
notably those with severe coronary artery disease (three-
vessel or left main artery stenosis) or diabetic dialysis
patients as suggested by the recent study [41]. (4) Finally,
CAD is the leading cause of mortality and is a major risk
factor in all dialysis patients. To test the prognostic predic-
tive value of thallium imaging, only major coronary events
were considered. Non-coronary events of non-cardiac or
cardiac origin were excluded from the analysis. The prev-
alence of such non-coronary events was not significantly
different in the dialysis subgroups with normal or abnormal
thallium uptake. Three sudden deaths (2 in group 1) were
treated as coronary events although a coronary origin was
clearly established in only one case. However exclusion of
the two patients with unexplained SD did not affect the
prognostic value of thallium imaging. Myocardial revascu-
larization procedures were treated as coronary events
because the decision to revascularize was taken only after
the occurrence of a clinical coronary complication (acute
myocardial infarction or unstable angina) during the fol-
low-up except for asymptomatic patients presenting severe
coronary artery disease (three-vessel or left main coronary
artery stenosis). Thallium imaging results did not influence
decision to treat. Thus, in the present study, four patients
received a revascularization treatment, three following the
occurrence of unstable angina and only one because of the
discovery of three-vessel disease at coronary angiography in
the absence of any coronary evolutivity. Even after exclu-
sion of these four patients from analysis, coronary out-
comes among the 56 remaining patients remained signifi-
cantly more frequent in patients with abnormal SPECT
than in those with normal SPECT (31% (4 of 13) versus 9%
(4 of 43; P 5 0.02). Using thallium imaging as a routine
diagnostic method raises the question of its avaibility and
cost. Centers of nuclear medicine are now widespread and
the cost of thallium imaging is acceptable, being between
that of the classical exercise testing and that of coronary
angiography. The actual cost-benefit ratio of the thallium
imaging for dialysis patients, although intuitively favorable,
should be precisely determined.
In conclusion, in asymptomatic dialysis patients, dipyrid-
amole-exercice thallium imaging is an accurate diagnostic
and prognostic method. Normal stress-thallium imaging, in
particular, enables significant coronary stenosis to be ruled
out and to identify patients at low risk of coronary events.
Further studies comparing stress-thallium imaging to other
diagnostic strategies are required to assess its potential
contribution to the diagnostic strategy for dialysis patients.
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APPENDIX
Abbreviations used in this article are: CABG, coronary artery bypass
graft surgery; CAD, coronary artery disease; EF, ejection fraction; LAD,
left anterior descending artery; LVH, left ventricular hypertrophy; LVM,
left ventricular mass; MI, myocardial infarction; NSD, non-sudden death;
PTCA, percutaneous transluminal coronary angioplasty; RA, right coro-
nary artery; SD, sudden death; SPECT, stress-thallium 201 single photon
emission computer tomography.
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